Clinical Development Advisors

Barry Greenberg

Ph.D Director, Institute for the Prevention and Treatment of Alzheimer’s Disease at Johns Hopkins Appointed by the NIA to chair an international committee to strategize the future structure of the US Alzheimer Research Center network to augment capacity to develop prevention & treatment by 2025.

Philip Scheltens

MD, Ph.D Director, Alzheimer’s Centre, VU University Medical Centre, Amsterdam, Cognitive Neurologist, Alzheimer Basic & Clinical Researcher Appointed by the NIA to chair an international committee to strategize the future structure of the US Alzheimer Research Center network to augment capacity to develop prevention & treatment by 2025.

Serge Gauthier

C.M., MD, FRCPC. Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging, experienced in the design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors. Special interest in non-cognitive outcomes of clinical trials (ADL , behavior) – co-chaired the Canadian Consensus Conference on Dementia (CCCDTD4) 2012.

Geert Jan Groeneveld

MD Ph.D – CSO/CMO at Centre For Human Drug Research, Univ. of Leiden, Clinical Neurologist and NeuroPharmacologist,  PI on Memogain SAD and MAD Clinical Trials ,Extensive experience with early stage AD drug development and assessment.

 

 

WordPress Login Protected by Clef